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STUDY QUESTION: What are the data on ART and IUI cycles, and fertility preservation (FP) interventions reported in 2017 as
compared to previous years, as well as the main trends over the years?
SUMMARY ANSWER: The 21st ESHRE report on ART and IUI shows the continual increase in reported treatment cycle numbers in
Europe, with a decrease in the proportion of transfers with more than one embryo causing an additional slight reduction of multiple
delivery rates (DR) as well as higher pregnancy rates (PR) and DR after frozen embryo replacement (FER) compared to fresh IVF and ICSI
cycles, while the number of IUI cycles increased and their outcomes remained stable.
WHAT IS KNOWN ALREADY: Since 1997, ART aggregated data generated by national registries, clinics or professional societies have
been gathered and analyzed by the European IVF-monitoring Consortium (EIM) and communicated in a total of 20 manuscripts published
in Human Reproduction and Human Reproduction Open.
STUDY DESIGN, SIZE, DURATION: Data on European medically assisted reproduction (MAR) are collected by EIM for ESHRE on a
yearly basis. The data on treatments performed between 1 January and 31 December 2017 in 39 European countries were provided by
either National Registries or registries based on personal initiatives of medical associations and scientific organizations.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Overall, 1382 clinics offering ART services in 39 countries reported a total
of 940 503 treatment cycles, including 165 379 with IVF, 391 379 with ICSI, 271 476 with FER, 37 303 with preimplantation genetic testing
(PGT), 69 378 with egg donation (ED), 378 with IVM of oocytes, and 5210 cycles with frozen oocyte replacement (FOR). A total of 1273
institutions reported data on 207 196 IUI cycles using either husband/partner’s semen (IUI-H; n¼ 155 794) or donor semen (IUI-D;
n¼ 51 402) in 30 countries and 25 countries, respectively. Thirteen countries reported 18 888 interventions for FP, including oocyte, ovar-
ian tissue, semen and testicular tissue banking in pre- and postpubertal patients.
MAIN RESULTS AND THE ROLE OF CHANCE: In 21 countries (20 in 2016) in which all ART clinics reported to the registry, 473
733 treatment cycles were registered for a total population of approximately 330 million inhabitants, allowing a best-estimate of a mean of
1435 cycles performed per million inhabitants (range: 723–3286).
Amongst the 39 reporting countries, the clinical PR per aspiration and per transfer in 2017 were similar to those observed in 2016 (26.8%
and 34.6% vs 28.0% and 34.8%, respectively). After ICSI the corresponding rates were also similar to those achieved in 2016 (24% and
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33.5% vs 25% and 33.2% in 2016). When freeze all cycles were removed, the clinical PRs per aspiration were 30.8% and 27.5% for IVF
and ICSI, respectively.
After FER with embryos originating from own eggs the PR per thawing was 30.2%, which is comparable to 30.9% in 2016, and with em-
bryos originating from donated eggs it was 41.1% (41% in 2016). After ED the PR per fresh embryo transfer was 49.2% (49.4% in 2016)
and per FOR 43.3% (43.6% in 2016).
In IVF and ICSI together, the trend towards the transfer of fewer embryos continues with the transfer of 1, 2, 3 and 4 embryos in
46.0%, 49.2%, 4.5% and in 0.3% of all treatments, respectively (corresponding to 41.5%, 51.9%. 6.2% and 0.4% in 2016). This resulted in a
reduced proportion of twin DRs of 14.2% (14.9% in 2016) and stable triplet DR of 0.3%. Treatments with FER in 2017 resulted in a twin
and triplet DR of 11.2% and 0.2%, respectively (vs 11.9% and 0.2% in 2016).
After IUI, the DRs remained similar at 8.7% after IUI-H (8.9% in 2016) and at 12.4% after IUI-D (12.4.0% in 2016). Twin and triplet DRs
after IUI-H were 8.1% and 0.3%, respectively (in 2016: 8.8% and 0.3%) and 6.9% and 0.2% after IUI-D (in 2016: 7.7% and 0.4%). Amongst
18 888 FP interventions in 13 countries, cryopreservation of ejaculated sperm (n¼ 11 112 vs 7877 from 11 countries in 2016) and of
oocytes (n¼ 6588 vs 4907 from eight countries in 2016) were the most frequently reported.
LIMITATIONS, REASONS FOR CAUTION: As the methods of data collection and levels of reporting vary amongst European coun-
tries, interpretation of results should remain cautious. Some countries were unable to deliver data about the number of initiated cycles
and deliveries.
WIDER IMPLICATIONS OF THE FINDINGS: The 21st ESHRE report on ART, IUI and FP interventions shows a continuous increase
of reported treatment numbers and MAR-derived livebirths in Europe. Being already the largest data collection on MAR in Europe, efforts
should continue to optimize data collection and reporting with the perspective of improved quality control, transparency and vigilance in
the field of reproductive medicine.
STUDY FUNDING/COMPETING INTEREST(S): The study has received no external funding and all costs are covered by ESHRE.
There are no competing interests.
Key words: IVF / ICSI / IUI/ / egg donation / frozen embryo replacement / surveillance / vigilance / registry / data collection/ fertility
preservation
Introduction
This is the 21st annual report of the European IVF-monitoring
Consortium (EIM) under the umbrella of ESHRE, assembling the data
on ART, IUI and fertility preservation (FP) reported by 39 participating
European countries in 2017 (Supplementary Table SI).
Eighteen previous annual reports published in Human Reproduction
(https://www.eshre.eu/Data-collection-and-research/Consortia/EIM/
Publications.aspx) and two in Human Reproduction Open (De Geyter
et al., 2020; Wyns et al., 2020) covered treatment cycles from 1997
to 2016. As in previous reports, the printed version contains the five
most relevant tables. Twenty additional supplementary tables
(Supplementary Tables SI–SXX) are available online on the publisher’s
homepage. The presentation of the data is consistent with those pub-
lished in previous reports to allow easy comparison and assessment of
trends. For the second consecutive year, data on FP were collected
and added to this report.
Material and methods
Data collected on an aggregate basis were provided by 39 European
countries, covering treatments with IVF, ICSI, frozen embryo replace-
ment (FER), egg donation (ED), IVM, preimplantation genetic testing
(PGT; pooled data) and frozen oocyte replacement (FOR). With
regards to IUI, data for use of husband’s/partner’s semen (IUI-H)
and donor semen (IUI-D) were distinguished. The report includes
treatments started between 1 January and 31 December in 2017.
Data on pregnancies and deliveries represent the outcomes of treat-
ments performed in 2017. Data on FP, including numbers and types
of cryopreserved material and interventions for use of cryostored
material between 1 January and 31 December in 2017, were provided
and reported as aggregated data of events that occurred during a
1-year period.
The national representatives of the 44 countries that are members
of the EIM were asked to fill out questionnaires. The same data sets
as in 2016 for a total of 10 specific modules were sent using software
designed for the requirements of this data collection (Dynamic
Solutions, Barcelona, Spain). Any detected inconsistencies were clari-
fied through contacts between the administrator of the ESHRE central
office, V.G., and the national representative.
The data were analyzed and presented similarly to previous
reports, with some additional subgroups of interventions since the
report on 2016 data, and footnotes to the tables were added for
clarification on diverging results reported by individual countries, when
applicable.
The terminology used was based on the glossary of The
International Committee for Monitoring Assisted Reproductive
Technology (Zegers-Hochschild et al., 2017).
Results
Participation and data completeness
Table I shows the number of clinics offering ART services with all avail-
able treatment modalities and institutions performing IUI (IUI-H and
IUI-D). Compared to 2016, the total number of reporting clinics
(1381 in 2017 vs 1347 in 2016) and number of reported treatments
(940 503 in 2017 vs 918 159 in 2016, þ2.4%) increased. Amongst the
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Table I Treatment frequencies after ART in European countries in 2017.









IVF ICSI FER PGD ED IVM FOR All Women
15-45
Population
Albania 11 1 11 1 0 105 82 1 24 0 2 214
Armemia 6 5 9 5 513 642 675 0 459 0 15 2304
Austria 29 29 0 0 1702 5298 2801 0 218 0 0 10 019 5870 1137
Belarus 8 7 10 7 1171 1570 663 68 61 0 9 3542
Belgium 18 18 28 28 2819 13 133 12 881 1145 1334 149 76 31 537 14 411 2778
Bosnia-Herzegovina 6 2 6 2 82 80 0 0 0 0 162
Bulgaria 36 36 37 37 311 4644 1365 124 714 0 0 7158 4719 1015
Croatia 15 15 16 16 1607 2727 1389 1436 0 0 62 7221 8864 1682
Czech Republic 44 44 0 0 15 557 13 907 0 5328 0 0 34 792 16 547 3286
Denmark 23 23 51 50 7262 6394 2726 345 798 0 19 17 544 15 783 3045
Estonia 6 6 6 6 637 1203 890 13 216 0 0 2959 11 705 2249
Finland 16 16 21 21 2471 1790 3584 97 645 0 0 8587 7519 1558
France 103 103 183 183 23 538 44 165 37 469 1452 1459 120 617 108 820 8528 1620
Germany 134 127 0 0 18 679 53 290 27 234 0 0 0 263 99 466
Greece 37 29 37 29 2166 13 588 5192 1534 5008 9 50 27 547
Hungary 14 13 0 0 1386 4022 0 0 23 0 0 5431
Iceland 1 1 1 1 259 221 267 0 65 0 0 812 11 498 2400
Italy 204 204 366 366 8049 44 965 17 281 3133 4864 0 1391 79 683 7335 1316
Kazakhstan 15 8 0 0 1664 3497 2416 1422 1103 0 0 10 102
Latvia 6 3 6 3 265 581 549 2 159 0 15 1571
Lithuania 6 5 6 5 395 187 2 0 0 0 584
Luxembourg 1 1 0 0 260 457 429 0 0 0 0 1146 9482 1904
Malta 2 2 3 0 17 214 0 0 0 0 155 386 3893 811
Moldova 4 3 5 0 960 346 0 0 0 0 1306
Montenegro 5 4 5 4 0 582 84 0 0 0 0 666
North-Macedonia 7 5 2 0 421 2100 277 0 142 0 0 2940
Norway 11 11 10 10 3963 2997 4476 0 0 0 0 11 436 11 566 2175
Poland 42 42 0 39 465 14 100 10 390 1242 1257 18 335 27 807 4712 723
Portugal 24 24 26 26 2646 3681 2317 275 1292 5 48 10 264 5387 997
Romania 19 10 19 10 1168 1732 1452 14 29 0 2 4397
Russia 220 159 0 0 38 874 48 739 35 979 5228 7777 20 594 137 211
Serbia 18 1 18 1 147 75 34 0 0 0 1 257
Slovenia 3 3 2 2 1054 2092 1422 62 5 0 4 4639 8986 2245
Spain 247 239 366 301 6473 43 790 27 690 15 373 31 441 27 798 125 592
Sweden 17 17 0 0 6187 5906 7006 504 267 0 0 19 870
Switzerland 27 27 0 0 986 5013 4944 76 0 0 0 11 019 6595 1299
The Netherlands 13 13 0 0 6417 7574 13 469 497 0 0 0 27 957 8936 1637
Ukraine 48 40 17 17 849 10 904 9080 1634 1134 0 7 23 608
UK 85 85 103 103 20 953 22 594 20 443 1624 3556 30 747 69 947 5392 1080
All 1531 1381 1370 1273 165 379 391 379 271 476 37 303 69 378 378 5210 940 503 7662 1435
Treatment cycles in IVF and ICSI refer to initiated cycles.
For Austria, Belgium and Iceland treatment cycles refer to aspirations. For Austria, Belgium and Lithuania the total number of initiated cycles was only available for IVF and ICSI to-
gether, being 10 216, 18 681 and 395, respectively.
For the Czech Republic and Lithuania, no distinction between IVF and ICSI is made. All cycles are counted as ICSI.
Treatment cycles in frozen embryo replacement (FER) refer to thawings.
For Croatia, Finland, Sweden and the Netherlands, treatment cycles refer to transfers.
Treatment cycles in PGD contain both fresh and frozen cycles and refer to initiated cycles in the fresh cycles and aspirations in the frozen cycles.
Treatment cycles in egg donation (ED) refer to donation cycles and contain fresh and frozen cycles.
ED fresh: For Bulgaria, France and Iceland treatment cycles refer to aspirations.
Treatment cycles in IVM refer to aspirations.
Treatment cycles in frozen oocyte replacement (FOR) refer to thawings, for Finland it refers to transfers.











































51 European countries, 44 are EIM members including 28 that are
members of the European Union and 39 (40 in 2016) provided data
(Supplementary Table SI). Non-EIM members are mainly small coun-
tries not offering ART services. Cyprus, Georgia, Ireland, Slovakia and
Turkey failed to deliver data (11.3% of EIM members, as in 2016). In
21 countries (53.8% of reporting countries, 45% in 2016) all of the
ART clinics within the country reported data sets. Amongst 1531
known IVF clinics in Europe, 1381 clinics reported their data (90.1%;
91.8% in 2016). Similar to 2016, the four European countries with the
largest treatment numbers in 2017 were Spain (125 592; 140 909 in
2016), Russia (137 211; 121 232 in 2016), France (108 820; 104 773
in 2016) and Germany (99 466; 99 226 in 2016).
Size of the clinics and reporting methods
The size of reporting clinics between and inside countries, defined by
the number of treatment cycles, remains highly variable
(Supplementary Table SII). In 2017, clinics with cycle numbers between
200–499 and 500–999 were the most common (25.9% and 26.3%,
respectively vs 29.5% and 26%). The proportion of clinics performing
more than 1000 treatment cycles per year is comparable to 2016
(18.9% vs 19.4% in 2016). Small clinics providing less than 100 treat-
ments cycles per year were present in 24 countries (57% of the
countries).
Registry requirements and reporting methods for each country are
presented in Supplementary Table SIII. Data collection was either vol-
untary (15 out of 39 countries) or compulsory. Nineteen countries
had only a partial reporting and provided the data mainly on a volun-
tary basis (15/19 countries) to medical organizations (9 countries), to
the national health authority (2 countries) or as a single person who
took the initiative (3 countries). One country reported as personal
initiative and to the National Health Authority and one country to a
medical organization and the National Health Authority.
By contrast, complete reporting was mostly achieved when data
collection was compulsory (20/21 countries) with subsequent data
communication to the national health authority (all but four countries).
Transfer of data was mostly done on an aggregate basis (24 coun-
tries/39).
Number of treatment cycles per technique
and availability
In 2017, 940 503 treatment cycles were reported to EIM (22 344
more than in 2016, þ2.4%). Since 1997, increasing numbers of clinics
reported to EIM to reach a total 10 713 407 treatments cycles and
the birth of more than 2 059 975 infants (Table II). As seen in Table I,
10 countries reported fewer treatment cycles and, compared to 2016,
Croatia was now able to provide data, whereas Ireland and Cyprus
not. Furthermore, the largest increments in reported treatment num-
bers were observed for Kazakhstan (þ 5642, þ3 clinics) and Russia
(þ15 976, þ8 clinics). Table I shows the numbers of treatment cycles
per technique in 2017: ICSI remains the most used (391 379, 41.6%
of all treatment cycles versus 407 222, 44.4% in 2016). Cycles of IVF,
FER, ED, FOR, PGT and IVM represented 17.6%, 28.9%, 7.4%, 0.5%,
4% and 0.0004% of all cycles, respectively. While the distribution of
the available techniques remained similar to 2016 (respectively, 17%,
27%, 8.1%, 0.5%, 2.9% and 0.0007%), reported cycle numbers
increased for IVF, FER, FOR and PGT and decreased for ICSI, ED and
IVM. The steepest rise in treatment numbers was observed for PGT
(þ37.8%, þ 27.4% in 2016) and FER (þ8.2%, þ13.9% in 2016).
However, while in 2016, ED and IVM cycle numbers increased
(þ14.7% and þ246.8%, respectively), a decrease of 6.1% and
42.2% was observed in 2017. The proportion of FER relative to fresh
treatments (IVFþICSI) is still on the rise (48.9%, versus 44.1% in 2016,
40.3% in 2015 and 37.8% in 2014). Denmark, Hungary and Malta did
not report FER in 2017. The highest proportions of FER treatments
(calculated as FER/(FERþICSIþIVF)) were reached in Bosnia-
Herzegovina (49.4%), The Netherlands (49%), Czech Republic
(47.2%), Finland (45.7%), Switzerland (45.2%), Belgium (44.7%),
Albania (43.9%) and Ukraine (43.6%), with an overall proportion of
32.6% (Fig. 1).
Figure 1 shows the evolution and continuing preponderance
of ICSI over conventional IVF. Amongst a total of 556 758 fresh
treatments (ICSIþIVF), 70.3% (72.3% in 2016) were performed
with ICSI.
The number of cycles per million women of reproductive age
and per million inhabitants is shown in Table I and Supplementary
Table SIV. Availability of ART was calculated for the 21 countries with
full coverage (Supplementary Table SIV). While there is a huge
......................................................................................................
Table II Number of institutions offering ART services,
treatment cycles and infants born after ART in Europe,
1997–2017.




1997 18 482 203 225 35 314
1998 18 521 232 225 þ14.3 21 433
1999 21 537 249 624 þ7.5 26 212
2000 22 569 275 187 þ10.2 17 887
2001 23 579 289 690 þ5.3 24 963
2002 25 631 324 238 þ11.9 24 283
2003 28 725 365 103 þ12.6 68 931
2004 29 785 367 056 þ0.5 67 973
2005 30 923 419 037 þ14.2 72 184
2006 32 998 458 759 þ9.5 87 705
2007 33 1029 493 420 þ7.7 96 690
2008 36 1051 532 260 þ7.9 107 383
2009 34 1005 537 463 þ1.0 109 239
2010 31 991 550 296 þ2.4 120 676
2011 33 1314 609 973 þ11.3 134 106
2012 34 1354 640 144 þ4.9 143 844
2013 38 1169 686 271 þ7.2 149 466
2014 39 1279 776 556 þ13.1 170 163
2015 38 1343 849 811 þ10.2 187 542
2016 40 1347 918 159 þ8.0 195 766
2017 39 1382 940 503 þ2.4 198 215
Total 10 713 407 2 059 975





























































..variability in availability when all techniques are considered (range:
3893–16 547 per million women aged 15–45 years), ART was most
available in Czech Republic and least available in Malta. Hence, corre-
sponding proportions of newborns resulting from ART were 5.4% and
1.1% of all newborns in these countries. Other countries that reported
high proportions were Denmark (5.6%), Iceland (5.6%), Estonia (5.3%)
and Slovenia (5.3%).
Pregnancies and deliveries after treatment
Table III shows pregnancy and delivery rates (DR) after IVF or ICSI
and after FER (after both IVF and ICSI). As numbers of initiated cycles
have constantly been incompletely reported, outcome data were
calculated per aspiration.
Amongst the 39 reporting countries, 35 were able to provide both
pregnancy and delivery data per aspiration after IVF (n¼ 30) and/or
ICSI (n¼ 35). For FER when considering thawing cycles, 29 and 28
countries were able to report pregnancy and delivery rates, respec-
tively. Supplementary Table SIV shows the numbers of deliveries for
the 21 countries with full coverage of the reporting.
Pregnancy and delivery rates (for all types of treatment cycles) var-
ied significantly from one country to another, as in previous years.
Per aspiration, pregnancy rates (PR) ranged from 18.4% to 42.3%
and DR from 10.4% to 40.9% in fresh cycles after IVF or ICSI (when
considering data from countries able to provide data excluding the
freeze-all cycles). Pregnancy and delivery rates per thawing for FER
varied between 22% and 49.1% and between 3.2% and 37.8%, respec-
tively. Overall, pregnancy and delivery rates were higher for FER cycles
(per thawing) than for both fresh IVF and ICSI cycles (per aspiration)
(Table III).
When considering the stage of replaced embryos, data showed PR
for blastocyst transfers to be higher (38.5% vs 27.2% for cleavage stage
embryos for FER and 41.7% vs 29.4% for cleavage stage embryos, for
fresh IVF and ICSI cycles, respectively).
For the fourth time, «freeze all» cycles were collected
(Supplementary Tables SV and SVI) including either freezing of all
oocytes reported by 10 countries for IVF (10 in 2016 and 6 in 2015)
and 17 countries for ICSI (15 in 2016 and 14 in 2015), or of all
embryos by 22 countries for IVF (22 in 2016 and 21 in 2015) and
27 countries for ICSI (22 in 2016 and 24 in 2015). The highest propor-
tions of freeze all cycles per aspiration for oocytes and for embryos to-
gether were 5.4% (IVF) (5.1% in 2016) and 49.1% (ICSI) (28.9% in
2016), respectively.
Cycle numbers, aspirations, transfers, pregnancies, deliveries in IVF,
ICSI and FER (after both IVF and ICSI) by country are presented in the
Supplementary Tables SV–SVII.
ED cycle numbers were available for 21 countries (26 in 2016) al-
though 26 (29 in 2016) provided outcome data (Supplementary
Table SVIII). Most ED cycles were reported from Spain, the Czech
Republic and Russia. The number of aspirations of donated oocytes
was 34 443 (33 406 in 2016) that led to 26 447 fresh transfers (28
451 in 2016), while the replacements of frozen oocytes (FOR) were
14 129 (11 757 in 2016). The PR per embryo transfer were 49.2%
(49.4% in 2016) for freshly donated oocytes and 41.1% (41% in
2016) for thawed oocytes although a high variability was seen be-
tween countries, ranging from 0% (2 cycles) to 61.6% for fresh
oocytes and from 23.1% to 62.2% for thawed oocytes. Overall, 21
137 deliveries were reported (22 497 in 2016 and 19 849 in 2015)
and pregnancy and delivery rates per transfer were higher than in
cycles with own gametes (partner donation) both for fresh (IVF and
ICSI) and FER cycles.
Age distribution
As seen in Supplementary Tables SIX and SX, age distributions of
women treated with IVF and ICSI varied between countries. Some
countries were not able to provide age categories (10 for IVF and six
for ICSI). The highest percentage of women aged 40 years and older
undergoing aspiration for IVF was found in Greece (as in 2016),
Figure 1. Proportion of IVF versus ICSI and frozen embryo replacement (FER) in Europe, 1997–2017.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































whereas the highest percentage of women aged <34 years was found
in Ukraine (Montenegro in 2016). For ICSI the highest percentage of
women aged 40 years and older undergoing aspiration was found in
Greece (as in 2016), whereas the highest percentage of women un-
dergoing aspiration aged <34 years was recorded in Albania (in
Kazakhstan in 2016 and Albania in 2015). An age-dependent decrease
of pregnancy and delivery rates for IVF and ICSI cycles was reported
as expected, with pregnancy and delivery rates in women aged
40 years and older ranging between 5.9% and 32.5%, and 0% and
20%, respectively. Concerning FER (Supplementary Table SXI), the age
related decline was still visible and DR recorded amongst women aged
40 years and older were between 0 and 36.4%.
In ED cycles (Supplementary Table SXII), the age of the recipient
women had no influence on outcomes.
Numbers of embryos transferred and
multiple births
Subgroups defined by the number of embryos replaced per transfer
procedure after IVF and ICSI together as well as multiple birth rates
are presented in Table IV. Six countries did not report on the number
of replaced embryos or on multiplicity. While overall most transfers in-
volved the replacement of two embryos (49.2%, 51.9% of the transfer
cycles in 2016), the proportion of transfers of only one embryo per
cycle is still on the rise (46% vs 41.5% in 2016), and the number of
transfers of three or more embryos continued to decrease (Fig. 2A).
Thirteen countries reported more than 50% of single embryo transfers
(elective or not) (10 in 2016) (same 10 as in 2016 plus Estonia, France
and Latvia). For the first time, none of the reporting countries carried
out more than 50% of their transfers with three embryos (in 2016
only Serbia did). The highest proportion of transfers of four or more
embryos was recorded in Greece (4% vs 4.2% in 2016). For the
second consecutive year, the embryo stage at transfer was col-
lected. Taking into account that the embryo stage at transfer was
unknown for 23.2% of the fresh (IVFþICSI) cycles, 44.1% (41.9% in
2016) of the transfers were performed at the blastocyst stage. The
corresponding figure for FER was 64.1% (62.2% in 2016). Such infor-
mation was not available for each of the subgroups for numbers of
embryos replaced.
As a result of decreasing numbers of embryos replaced per transfer,
the proportion of both twin and triplet deliveries continued to de-
crease (Fig. 2B). In 2017, twin and triplet rates for fresh IVF and ICSI
cycles together were 14.2% (range 2.1–28.6) and 0.3% (range: 0–1.8),
respectively. Corresponding results for FER were 11.2% and 0.2%. In
the three countries with rates of single embryo replacement above
80% in fresh cycles (93.4% for Iceland, 91.3% for Finland and 84.2%
for Sweden), twin rates were as low as 3.5% (for Iceland and Sweden,
not available for Finland).
Additional information on pregnancies and deliveries is provided in
Supplementary Tables SXIII and SXIV. The reported incidence of preg-
nancy loss was 16.6% (16.4% in 2016) after IVFþICSI and 18.3%
(18.6% in 2016) after FER. The proportion of recorded lost to follow-



































































































































































































































































































































































































































































































































































































































































































































Perinatal risks and complications
Data on premature deliveries in 2017 were available from 19
countries (18 countries in 2016). Premature DR pooled for fresh
IVF and ICSI, FER and ED and according to multiplicity are pre-
sented in Supplementary Table SXV. The incidence of extreme
preterm birth (20–27 gestational weeks at delivery) was 1.1% in
singletons (1.1% in 2016), 3.4% in twins (3.3% in 2016) and 10.7%
in triplets (8.4% in 2016). Very premature birth rates (28–32 ges-
tational weeks at delivery) were recorded in 2.4% of singletons
(2.2% in 2016), 10.3% of twin pregnancies (10.5% in 2016) and
21.7% in triplet pregnancies (in 2016: 45%). Proportions of pre-
mature deliveries before 37 weeks according to multiplicity are
shown Fig. 3. Term deliveries (37 weeks) were achieved in
86.6% (85.9% in 2016) of singleton pregnancies, 45.2% (44.1% in
2016) of twin pregnancies and 27% (8.8% in 2016) of triplet
pregnancies.
Complications related to oocyte retrievals were reported by 32
countries (33 in 2016) and foetal reductions by 24 countries (26 in
2015) (Supplementary Table SXVI). The total reported number of
OHSS (Grades 3–5) was 1839 (1928 in 2016) corresponding to a
reported incidence of 0.20% (0.21% in 2016). Other complications
were less frequent (1484; 1471 cases in 2016) with a total reported
incidence of 0.16% (0.2% in 2016), with bleeding being the most
reported (0.1%, identical to 2016). In 2017 one maternal death was
reported (none in 2016). Foetal reductions were reported in 599
cases (553 in 2016), the majority from UK, Belgium and Spain, as in
2016.
PGT/PGT-A
Table I includes PGT and PGT for aneuploidies (PGT-A) activities,
which were reported from 25 countries (22 in 2016, 23 in 2015). The
main contributors were Spain, Russia and Italy. The number of treat-
ment cycles amounted to 37 303 representing 4.3% of initiated
IVFþICSI and FER cycles together (27 069; 3.3% in 2016). More
details on PGT/PGT-A activities can be found in the annual reports of
the ESHRE PGT Consortium (Coonen et al., 2020). These involved 24
120 fresh cycles and 13183 thawings, resulting in 5109 fresh and 11
205 frozen embryo transfers. In total, 1995 pregnancies (39.0% per
transfer) and 1685 deliveries (33.0% per transfer) resulted from fresh
cycles. Corresponding figures for FER were 5601 (50.0% per transfer)
and 4302 (38.4% per transfer).
IVM
A total of 378 treatments with IVM were reported from eight coun-
tries (654 treatments from eight countries in 2016) (Table I). Most
IVM cycles were recorded in Belgium (in Russia for 2016). A total of
184 transfers resulted in 51 pregnancies (27.7% per transfer) and 31
deliveries (16.8% per transfer).
Figure 2. Embryo transfer and multiple births in Europe, 1997–2017. (A) Number of embryos transferred in IVF and ICSI during fresh
cycles. (B) Percentages of twin and triplet deliveries.
Figure 3. Proportion of premature deliveries (<37 weeks
of gestation in relation to pregnancies 37 week of gesta-
tion) in singleton, in twin and in triplet pregnancies in
Europe, 2006–2017.




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A total number of 5210 thawing cycles were reported by 21 countries
(4878 from 15 countries in 2016) (Table I) with Italy and Spain being
the largest contributors (1391 and 798 cycles, respectively). Amongst
3951 transfers, 1086 resulted in pregnancies (27.5%; 29.5% in 2016)
and 831 in deliveries (21%; 21% in 2016).
IUI
Data on IUI with husband semen (IUI-H) or using donors’ semen (IUI-
D) were collected by a total of 1273 institutions (1197 in 2016) in 30
and 25 countries (28 and 23 in 2016), respectively (Table V). Amongst
155 794 IUI-H (162 948 in 2016) and 51 402 IUI-D (50 467 in 2016)
reported cycles, the numbers were the highest for IUI-H in Spain, Italy
and Belgium, and for IUI-D in Spain, Denmark and Belgium
(Supplementary Tables SXVII and SXVIII).
DR could be calculated for 151 537 IUI-H cycles (8.9% as in 2016)
and 51 402 for IUI-D cycles (12.4% vs 12.4% in 2016).
Singleton deliveries were the most frequent regardless of the age
group with an overall rate of 91.6% for IUI-H and 92.9% for IUI-D
(91.0% in IUI-H, 91.9% in IUI-D in 2016). Twin and triplet rates were
8.1% and 0.3%, respectively, for IUI-H, and 6.9% and 0.2% for IUI-D,
respectively (in 2016: 8.8% and 0.3%, respectively, for IUI-H and 7.7%
and 0.4%, respectively, for IUI-D).
Sum of fresh and FER (‘cumulative’) DR
Supplementary Table SXIX provides an estimate of a cumulative DR
(different from a true cumulative DR, which is based on all transfers
resulting from one aspiration). It was calculated as the ratio between
the total number of deliveries from fresh embryo transfers and FER
performed during a year (numerator) and the number of aspirations
during the same year (denominator). The calculation included data
from 34 countries (38 countries in 2016) where an overall rate of
30.8% (29.6% in 2016) was recorded. The gain taken from additional
FER (over DR from fresh embryo transfers) was 12.3% (10.5% in
2016), with the highest benefits recorded for Ukraine (þ29.8%),
Finland (þ21.1%), Sweden (þ20.2%), Armenia (þ19.7%) and Latvia
(þ19.2%), and the lowest for Serbia (0%), Montenegro (þ3.4%),
North-Macedonia (þ3.8%), Bulgaria (þ5.8%) and Belarus (þ6.2%).
Cross-border reproductive care
Eight countries reported data on cross-border patients: Albania,
Belarus, Denmark, Poland, Portugal, Slovenia, Spain and Switzerland.
A total of 16 733 cycles (19 239 in 2016) were reported, 16.9%
(22.1% in 2016) of which involved IVF/ICSI with the couple’s own
gametes, 50.1% (46.6% in 2016) were EDs and 25.8% (21.8% in 2016)
were IVF or ICSI with semen donation. Additionally 7298 IUI with
sperm donation (7062 in 2016) were registered. Information regarding
the countries of origin was very incomplete and not reliable enough to
obtain any conclusive information. The main reasons reported by
patients were to have access to a technique not legally available in
their home country (41.9%; 39.1% in 2016) or to seek a higher quality
treatment (25.7%; 23.6% in 2016). In 13 551 cycles (mainly from
















































































































































































































































































































































































































































































































































For the second year data on FP were reported. Fourteen countries
(11 in 2016) provided data on a total number of 18 888 interventions
(13 689 in 2016) (Supplementary Table SXX) in pre- and postpubertal
patients, both for medical and non-medical reasons. The majority of
interventions consisted of the cryopreservation of ejaculated sperm
(n¼ 11 112 from 13 countries; 7877 from 11 countries in 2016) and
the cryopreservation of oocytes (n¼ 6588 from 13 countries;
n¼ 4907 from eight countries in 2016). Ovarian tissue cryopreserva-
tion was reported by three (2 in 2016) and 10 (7 in 2016) countries,
respectively, for pre- and postpubertal patients, with the use of post-
pubertal tissue through transplantation reported in three countries
(France, Italy and Spain). Testicular tissue cryopreservation in postpu-
bertal patients and prepubertal boys was reported from eight (six in
2016) countries and from four countries (Austria, Belgium, France and
Poland), respectively.
Discussion
This is the 21st annual report on ART, IUI and, for the second time,
FP activity data collected by EIM from European compulsory or volun-
tary registries. From 1997 to 2017, the EIM Consortium of ESHRE has
registered over 10 million treatments cycles (10 713 407) that have
led to the birth of over 2 million infants.
This report presents the analysis of data collected in 2017 from 39
European countries (40 in 2016). The number of European countries
participating has remained quite stable over the last years with only a
few non- participating countries (5 of 44 EIM members, 7 non-EIM
members including Azerbaijan, Kosovo and 5 countries that do not
provide ART services). The main reasons for not being able to send
data most likely appear to be either economic at centre and/or coun-
try level, regulatory or political (Calhaz-Jorge et al., 2020). Although
the participation of some countries has fluctuated over the years,
reported ART treatment numbers are still on the rise (þ2.4% as com-
pared to 2016) as are the number of infants born from ART (þ1.2%
compared to 2016).
Considering the importance of data collection to improve clinical
care, including vigilance on medically assisted reproduction (MAR
treatments) (De Geyter et al., 2016; Kissin, 2019) , EIM and the EU
affairs committee of ESHRE are striving to increase awareness of coun-
try competent authorities and EU DG SANTE, respectively, aiming at
reaching the highest level of completeness and harmonization of
European data on reproductive care. Amongst other actions, country
representatives and competent authorities have been invited to
ESHRE activities related to data collection (https://www.eshre.eu/
ESHRE2021/Programme/Precongress-Courses/Course-14-EIM).
Despite known challenges in data collection and after exclusion of
countries where ART is not available, the participation rate at the
country level is as high as 86.3% of European countries (88.7% of EIM
members) while at the level of IVF clinics the proportion of those
reporting data is at 90.1% (vs 91.8% in 2016; Wyns et al., 2020).
As previously, levels of completeness of the data are variable
amongst countries but 21 countries were able to send data from all
IVF clinics (20 in 2016, 18 in 2015 and 14 in 2014). Besides reaching a
higher number of countries able to provide complete data sets,
obtaining cycle-by-cycle data (15 countries in 2017) should be the
next priority to facilitate data interpretation and reliability.
Further progress towards higher quality of the data is expected
through harmonization of reported data by registries. In this regard,
core data sets on outcome parameters with definitions of collected
items have been established (https://www.eshre.eu/Data-collection-
and-research/Consortia/EIM). Collecting higher quality data is also in
line with future requirements and expectations at the EU level.
Meanwhile, owing to the variety of collection systems, the absence or
limited presence of data validation methods and quality control, and
differences in definitions and country or centre-specific practices (e.g.
freeze all cycles, embryo transfer policy, PGT-A), interpretation of the
data should remain cautious.
Being aware of the current EU objective of increased transpar-
ency on MAR care for all stakeholders, including the patient, data
on availability and cross-border care are of utmost importance.
Over the years, EIM has constantly recorded a high variability in
access to treatment between countries, ranging from 723 to 3286
per million inhabitants and 3893 to 15 783 per million females of
reproductive age in 2017.
So far, data generated by EIM on numbers of treatment cycles per
million inhabitants and per woman of reproductive age by country are
unique in Europe and very relevant to assess equity in access to infer-
tility care. Currently and as in 2016, 60% of countries with complete
data sets reach the historical estimated threshold of 1500 fresh ART
cycles needed for infertility care per million inhabitants (The ESHRE
Capri Workshop Group, 2001). However, owing to technological evo-
lutions in ART with increasing success rates and higher numbers of
FER treatment cycles over time (Fig. 1) (representing 48.9% of ART
cycles when fresh IVFþICSI cycles are used as the denominator vs
44.1% in 2016), such estimates may have become obsolete and de-
serve to be reassessed. In this regard, and to eliminate age differences
amongst countries, estimates should preferably use the number of
women of reproductive age as denominator. Moreover, as data on
cross-border patients were available for only eight countries (10 in
2016) such a low reporting represents another serious limitation when
it comes to estimating access to care.
Regarding treatment modalities, while ICSI remains the most applied
with a trend to stabilization of its use during recent years (Table I and
Fig. 1), FER is the second most used technique. A progressive increase
in the proportion of FER relative to fresh IVF and ICSI cycles has also
been recorded over the years (37.8% in 2014, 40.3% in 2015, 44% in
2016 and 48.9% in 2017). The high variability in the proportion of FER
cycles amongst countries that both report FER cycles and provide
complete data sets (ranging from 27.5% to 96.3%), reflects variable
practices in terms of stimulation protocols, embryo transfer policy and
embryo cryopreservation. Amongst others, freeze-all cycles, now reg-
istered since 2014 (Supplementary Table SV) and increasingly
reported, show proportions per aspiration ranging between 2.3% and
49.1% for embryos. Such differences should not be neglected when
analyzing data. For instance, lower overall pregnancy and DR for fresh
IVF and ICSI cycles (per aspiration) compared to FER cycles (per thaw-
ing) (Table III) need to be cautiously interpreted taking into account
variability in practices, including freeze-all cycles. Other evolutions,
such as increased frequency of vitrified-warmed blastocyst transfers,
could also explain better outcomes after FET.





























































































Cumulative DR per cycle or per aspiration are therefore better out-
come indicators to assess treatment effectiveness (De Neubourg
et al., 2016). So far, the EIM consortium has gathered aggregated data
that preclude the calculation of true cumulative delivery and livebirth
rates. Hence, a proxy-indicator for true cumulative rates, based on the
addition of outcomes of fresh and FER during the same calendar year,
has been considered. Taking into account data from 34 countries, cu-
mulative DR reached 30.8% (29.6% in 2016) during the 1-year period.
Important trends have been noted over time in EIM data sets
(Ferraretti et al., 2017; De Geyter et al., 2020). Amongst these, a re-
duction in the number of replaced embryos per transfer (Fig. 2A) and
of multiple births (Fig. 2B) were highlighted. As a result of promoting a
higher awareness amongst professionals, the proportion of transfers of
only one embryo (whether elective or not) continues to rise (46% vs
41.5% in 2016), and the number of transfers of three or more em-
bryos continues to decrease. Paralleling this trend, multiple birth rates
decrease, with the lowest rates observed (3.5%) when the proportion
of single embryo transfers is above 80%. As recorded twin and triplet
rates were slightly lower for FER, as in 2016, the increase in FER could
also have influenced multiple birth rates. The impact of foetal reduc-
tions remains, however, unknown: 61% of the 39 countries in 2017
reported data on foetal reductions, but only a limited number of the
countries (17) actually performed them.
In the future, it is highly expected that efforts will lead to the ulti-
mate goal of the birth of one healthy child (Land and Evers, 2003) per
embryo transfer and to a reduction of prematurity associated with
multiple births. Looking at the evolution of the proportions of deliver-
ies before 37 weeks according to multiplicity (Fig. 3), it is rather clear
that besides efforts to reduce triplets, the focus needs to be on reduc-
ing twins where preterm births are still as high as 45.2%, and extreme
and very preterm births increased by 3- and 4-folds compared to sin-
gletons, respectively.
Aiming at elective single embryo transfer but also at a reduced time
to pregnancy, the field has focused on prolonging embryo culture up
to the blastocyst stage. For the second time, in 2017 the proportion
of transfers at the blastocyst stage was collected and showed a slight
increase since 2016 (44.1% vs 41.9% for fresh transfers and 64.1% vs
62.2% for FER). While the benefit of blastocyst stage transfers on ART
outcomes is still a matter of debate (Glujovsky et al., 2016; Practice
Committee of ARSM, 2018), EIM data showed PR for blastocyst trans-
fers to be higher (41.7% vs 29.4% for cleavage stage embryos for IVF
and ICSI and 38.5% vs 27.2% for cleavage stage embryos for FER).
Unfortunately, data on deliveries by stage of embryo transfer were not
available.
With regard to the safety aspects of ART treatments, besides
multiplicity and prematurity, the reporting remains most likely poor
with the highest rate of complications for ovarian hyperstimulation
syndrome (0.2% similar to 2016) and a total incidence of other
complications at 0.16%. It is, however, noticeable that there was
one maternal death after ART reported in 2017 (Supplementary
Table SXVI).
The future of MAR registries should focus on levelling up the quality
of collected data towards complete and harmonized data allowing
comparisons of practices and identification of the safest and most effi-
cient care. The next priorities should include the health of the still
increasing numbers of children born from ART considering also that
evolution in the reproductive field will most likely be marked by in-
creasing needs for ART, owing to FP interventions linked to postpone-
ment of motherhood or gonadotoxic therapies and further
developments in PGT.
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Appendix
Contact persons who are collaborators and represent the data
collection programmes in participating European countries, 2017.
Albania
Prof. Orion Gliozheni, University Hospital for Obst & Gynecology,
Department of Obstetrics & Gynecology, Bul.B.Curri, Tirana, Albania.
Tel: þ355 4 222 36 32; Fax: þ355 4 2257 688; Mobile: þ355 68 20
29 313. E-mail: glorion@abcom.al
Armenia
Mr Eduard Hambartsoumian, Fertility Center, IVF Unit, 4 Tigvan
Nets, 375010 Yerevan, Armenia; Tel: þ374 10 544368; E-mail
Hambartsoumian@hotmail.com
Austria
Prof. Dr Heinz Strohmer, Dr Obruca & Dr Strohmer Partnerschaft
Goldenes Kreuz-Kinderwunschzentrum, Lazarettgasse 16-18, 1090
































































































Wien, Austria. Tel: þ43 401 111 400; Fax: þ43 401 111 401. E-mail:
heinz.strohmer@kinderwunschzentrum.at
Belarus
Dr Elena Petrovskaya (Alena Piatrouskaya), ART Centre ‘Embryo’,
Filimonova 53, 220053 Minsk, Belarus. Tel: þ375 293 830 570; E-mail:
elenaembryoby@gmail.com
Dr Oleg Tishkevich, Centre For Assisted Reproduction “Embryo”
Belivpul, Filimonova Str. 53, 220114 Minsk, Belarus. Tel: þ375 296
222 722; Fax: þ375 172 376 404; Mobile: þ375 296 222 722; E-mail:
tishol@tut.by
Belgium
Dr Kris Bogaerts, I-Biostat, Kapucijnenvoer 35 bus 7001, 3000
Leuven, Belgium. Tel: þ32 (0) 16 33 68 90; Fax: þ32 (0) 16 33 70
15. E-mail: Kris.Bogaerts@med.kuleuven.be
Prof. Christine Wyns, Gynaecology-Andrology, Cliniques
Universitaires Saint Luc, Service FIV- Andrology, Université Catholique
de Louvain; Av. Hippocrate, 10, 1200 Brussels, Belgium. Tel:
þ32 27646576; Fax þ32 27649050; Mobile þ32 477943374; E-mail:
christine.wyns@uclouvain.be
Bosnia
Prof. Dr Devleta Balic, Zavod za humanu reprodukciju ‘Dr Balic’,
Kojsino 25, 75000 Tuzla, Bosnia—Herzegovina. Tel: þ387 35 260
650; Mobile: þ387 611 402 22; E-mail drbalic@bih.net.ba
Prof. Dr Sanja Sibincic, Health Center Medico-S, Jevrejska 58/A,
78000 Banja Luka, Bosnia—Herzegovina. Tel: þ387 512 321 00;
Mobile: þ387 655 159 42; E-mail sanjasibincic@gmail.com
Bulgaria
Irena Antonova, ESHRE certified clinical embryologist (2011),
Ob/Gyn Hospital Dr Shechterev, 25-31, Hristo Blagoev Strasse, 1330
Sofia, Bulgaria. Tel: þ359 887 127 651; E-mail: irendreaming@gmail.
com
Croatia
Prof. Dr Hrvoje Vrcic, Zagreb University Medical School,
Obstetrics and Gynecology, Petrova 13, 10000 Zagreb, Croatia. Tel:
þ385 146 046 46; Fax: þ385 146 335 12; E-mail: Hrvoje.vrcic@
hilarus.hr
Dr Dejan Ljiljak, Clinical Hospital Center ‘Sestre milosrd’, Department
for Biology of Human Reproduction, Ob/Gyn Clinic, Vinogradska c. 29,
10000 Zagreb, Croatia. Tel: þ385 378 75 97; Fax: þ385 137 682 72;
Mobile: þ385 3787 125; E-mail: dejan.ljiljak@kbcsm.hr
Czech Republic
Dr Karel Rezabek, Medical Faculty, University Hospital, CAR-Assisted
Reproduction Center, Gyn/Ob Department, Apolinarska 18, 12000
Prague, Czech Republic. Tel: þ420 224 967 479; Fax: þ420 224 922
545; Mobile: þ420 724 685 276; E-mail: rezabek.ivf@seznam.cz
Mgr. Jitka Markova, Institute of Health Information and Statistics of
the Czech Republic, Palackeho namesti 4, 12801 Prague, Czech
Republic. Tel: þ420 224 972 832; Mobile: þ420 721 827 532; E-mail:
jitka.markova@uzis.cz
Denmark
Dr Josephine Lemmen, Vitanova, Fertility clinic, Vester Voldgade
106, 1552 Copenhagen, Denmark. Tel: þ45 333 371 01; E-mail:
jglemmen@gmail.com
Estonia
Dr Deniss S~oritsa, Tartu University Hospital and Elitre Clinic, Tartu,
Estonia. Tel: þ372 740 9930; Fax: þ372 740 9931; E-mail: soritsa@
hotmail.com
Finland
Prof. Mika Gissler, THL National Institute for Health and Welfare,
P.O. Box 30, 00271 Helsinki, Finland. Tel: þ385 29 524 7279; E-mail:
mika.gissler@thl.fi
Dr Sari Pelkonen, Oulu University Hospital, Department of
Obstetrics and Gynaecology, P.O. Box 23, 90029 Oys, Finland.
Tel:þ358 8 3153040, E-mail sari.pelkonen@fimnet.fi
France
Dr Bilal Majed, Agence de la biomedecine, 1 av stade de France, 93
Saint Denis, France; E-mail: bilal.majed@biomedecine.fr
Prof. Jacques de Mouzon, 15-29 rue Guilleminot, 75014 Paris,
France. Tel: þ33 143 224 679; Mobile: þ33 662 062 274; E-mail: jac-
ques.de.mouzon@gmail.com
Germany
Dr Andreas Tandler—Schneider; Fertility Center Berlin; Spandauer
damm 130; 14050 Berlin; Germany. Tel: þ49 30 233 20 81 10; Fax:
þ49 30 233 20 81 19; E-mail: tandler-schneider@fertilitycenter-berlin.de
Greece
Prof. Nikos Vrachnis, National Authority of Medically Assisted
Reproduction, Ploutarxou 3, P.O. 10675 Athens. Tel: þ30
6974441144; E-mail: nvrachnis@hotmail.com
Hungary
Prof. Janos Urbancsek, Semmelweis University, 1st Department of
Ob/Gyn, Baross utca 27, 1088 Budapest, Hungary. Tel: þ36 1 266 01
15; Fax: þ36 1 266 01 15; E-mail: urbjan@noi1.sote.hu
Prof. G. Kosztolanyi, University of Pecs, Department of Medical
Genetics and Child Development, Jozsef A.u; 7., 7623 Pecs, Hungary.
Tel: þ36 7 2535977; Fax: þ36 7 2535972; E-mail: gyorgy.kosztola-
nyi@aok.pte.hu
Iceland
Mr Hilmar Bjorgvinsson, IVF Klinikin Reykjavik, Alfheimum 74, 104
Reykjavik, Iceland. Tel: þ354 430 4000; Fax: þ354 430 4040; E-mail:
Hilmar.bjorgvinsson@ivfklinikin.is
Italy
Dr Giulia Scaravelli, Istituto Superiore di Sanità, Registro Nazionale
della Procreazione Medicalmente Assistita, CNESPS, Viale Regina
Elena, 299, 00161 Roma, Italy. Tel: þ3906 499 04 050; Fax: þ39064
99 04 324; E-mail: giulia.scaravelli@iss.it
Dr Roberto de Luca, Istituto Superiore di Sanità, Registro Nazionale
della Procreazione Medicalmente Assistita, CNESPS, Viale Regina
Elena, 299, 00161 Roma, Italy. Tel.: þ3906 499 04 320; E-mail:
roberto.deluca@iss.it
Kazakhstan
Prof. Dr Vyacheslav Lokshin, International Clinical Center for
Reproductology ‘Persona’, Utepova street 32a, 00506 Almaty,
Kazakhstan. Tel: þ7 727 382 7777; Mobile: þ7 701 755 8209; E-mail:
v_lokshin@persona-ivf.kz
Dr Sholpan Karibayeva, International Clinical Center for
Reproductology ‘Persona’, Utepova Street 32a, 00506 Almaty,
Kazakhstan. Tel: þ7 727 382 7777; E-mail: sh.karibaeva@gmail.com
Latvia
Dr Valeria Magomedova, Jusu Arsti Private Clinic, Apuzes 14, 1046
Riga, Latvia. Tel: þ371 678 700 29; Fax: þ371 678 704 29; E-mail:
godunova@inbox.lv
Lithuania
Raminta Bausyte, Vilnius University Hospital Santaros
Clinics, Santaros Fertility Center, Simono Staneviciaus 64-69, 07113
































































































Vilnius, Lithuania. Tel: þ370 620 86826; E-mail: raminta.bausyte@
gmail.com
Ieva Masliukaite, Academic Medical Center, Cener for Reproductive
Medicine, Ijburglaan 1086ZJ Amsterdam, The Netherlands. Tel: þ31
653 688 815; E-mail: i.masliukaite@amc.uva.nl
Luxembourg
Dr Caroline Schilling, Centre Hospitalier de Luxembourg, Centre de
Stérilité et de Médecine de Reproduction, Rue Fiederspiel 2, 1512
Luxembourg, Luxembourg. Tel: þ352 44 11 32 30; Mobile: þ352 66
13 13 912; E-mail: schilling.caroline@chl.lu
Malta
Dr Jean Calleja-Agius, University of Malta, 12, Mon Nid, Gianni
Faure Street, TXN2421 Tarxien, Malta. Tel: þ356 216 930 41;
Mobile: þ356 995 536 53; E-mail: jean.calleja-agius@um.edu.mt
Moldova
Prof. Dr Veaceslav Moshin, Medical Director at Repromed
Moldova, Center of Mother @ Child Protection, State Medical and
Pharmaceutical University ‘N.Testemitanu’, Bd. Cuza Voda 29/1,
Chisinau, Republic of Moldova. Tel: þ37322 263855; Mobile:
þ37369724433; E-mail: mosin@repromed.md; veaceslavmoshin@
yahoo.com
Montenegro
Dr Tatjana Motrenko Simic, Human Reproduction Center Budva,
Prvomajska 4, 85310 Budva, Montenegro. Tel: þ382 33402432;
Mobile: þ382 69 052 331; E-mail: motrenko@t-com.me
Dragana Vukicevic, Hospital ‘Danilo I’, Humana reprodukcija, Vuka
Micunovica bb, 86000 Cetinje, Montenegro. Tel: þ382 675 513 71;
E-mail: vukicevic.dragana@yahoo.com
The Netherlands
Dr Jesper M.J. Smeenk, Department of Obstetrics and Gynaecology,
St. Elisabeth Hospital Tilburg, Hilv, The Netherlands. Tel: þ31 13 539
31 08; Mobile þ31 622 753 853; E-mail: j.smeenk@elisabeth.nl
North Macedonia
Mr Zoranco Petanovski, Hospital ReMedika, Nas. Zelezara, 1000
Skopje, Macedonia. Tel: þ389 224 475 45, Fax: þ389 226 031 00;
E-mail: zpetanovski@yahoo.com
Norway
Dr Liv Bente Romundstad, Spiren Fertility Clinic, Nardoskrenten 11,
7032 Trondheim, Norway. Tel: þ47 73523000; Mobile þ47
90550207; E-mail libero@klinikkspiren.no
Poland
Dr Anna Janicka, VitroLive, Wojska Polskiego 103, 70-483 Szczecin,
Poland. Tel: þ48 91 88 69 260; E-mail anna.janicka@vitrolive.pl
Portugal
Prof. Dr Carlos Calhaz—Jorge, CNPMA, assembleia da Republica,
Palacio de Sao Bento, 1249-068 Lisboa, Portugal. Tel: þ351 21 391
93 03; Fax: þ351 21 391 75 02; E-mail: calhazjorgec@gmail.com
Ms Joana Maria Mesquita Guimaraes. Hospital Geral Santo Antonio,
Largo Professor Abel Salazar, 4050-011 Porto, Portugal. Tel: þ351 96
616 02 37; E-mail: joanamesquitaguimaraes@gmail.com
Ms Ana Rita Laranjeira, CNPMA, Assembleia da Republica, Palaio
de Sao Bento 1249-068 Lisboa, Portugal. Tel þ351 21 391 93 03; Fax
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